NasdaqCM - Nasdaq Real Time Price USD

GlycoMimetics, Inc. (GLYC)

Compare

0.2019

+0.0073

+(3.75%)

At close: April 11 at 4:00:02 PM EDT

0.1955

-0.01

(-3.17%)

After hours: April 11 at 7:24:28 PM EDT

US Penny Stocks To Watch In February 2025

As the U.S. stock market navigates a mixed trading environment, with indices like the S&P 500 retreating slightly from record highs, investors are keeping an eye on smaller opportunities that might offer potential value. Penny stocks, though often associated with higher risk due to their smaller size and less-established nature, can still present intriguing investment possibilities when backed by strong financials and growth prospects. In light of current market conditions, we explore three...

Simply Wall St. last month

GLYC
+3.75%
GSIT
GlycoMimetics and Crescent Biopharma Announce Merger Plans

GlycoMimetics ( (GLYC) ) has shared an update. GlycoMimetics and Crescent Biopharma have updated their investor presentation related to their proposed merger. This presentation highlights that the merger is not a solicitation for any securities transaction. GlycoMimetics plans to file relevant materials with the SEC, including a proxy statement, urging investors to review these documents carefully. Crescent Biopharma, launched by Paragon Therapeutics, focuses on advancing cancer therapies, parti

TipRanks 2 months ago

GLYC
+3.75%
GlycoMimetics: Q3 Earnings Snapshot

ROCKVILLE, Md. AP) — GlycoMimetics Inc. GLYC) on Wednesday reported a loss of $9.8 million in its third quarter.

Associated Press Finance 4 months ago

GLYC
+3.75%
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, announced management will present at the Jefferies London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT.

PR Newswire 4 months ago

GLYC
+3.75%
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

ROCKVILLE, Md., November 06, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, California, on December 7-10, 2024.

Business Wire 5 months ago

GLYC
+3.75%
US Penny Stocks To Watch In October 2024

As the U.S. stock market continues its upward trajectory with major indices like the Nasdaq hitting record highs, investors are keenly analyzing corporate earnings and economic data to gauge future opportunities. In this context, penny stocks—often representing smaller or newer companies—remain an intriguing area for those looking beyond established giants. Despite their name suggesting a bygone era, these stocks can offer significant potential when backed by strong financials and strategic...

Simply Wall St. 5 months ago

CVAC

GLYC
+3.75%
HNST
GlycoMimetics Announces Merger with Crescent Biopharma

GlycoMimetics ( (GLYC) ) has issued an update. GlycoMimetics, Inc. has announced a merger with Crescent Biopharma, aiming to enhance their presence in the biopharma sector. This merger, structured as a tax-free reorganization, will result in Crescent’s shareholders owning a significant majority of the combined entity. The transaction includes a substantial private placement of $200 million to support future growth and development. Both companies’ boards have approved the merger, expected to clos

TipRanks 5 months ago

GLYC
+3.75%
GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

ROCKVILLE, Md., October 29, 2024--GlycoMimetics, Inc. (NASDAQ: GLYC) announced today it has entered into an acquisition agreement with Crescent Biopharma, Inc. ("Crescent"), a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. Upon completion of the transaction, the Company plans to operate under the name Crescent Biopharma, Inc.

Business Wire 5 months ago

GLYC
+3.75%
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

ROCKVILLE, Md., October 29, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the Phase 2 analysis of the adaptive Phase 2/3 study of uproleselan being conducted by the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology in adults with newly diagnosed acute myeloid leukemia (AML) who are 60 years or older and fit for inten

Business Wire 5 months ago

GLYC
+3.75%
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

ROCKVILLE, Md., July 25, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the initiation of a strategic review and corporate restructuring plan. GlycoMimetics has engaged Lucid Capital Markets to act as a strategic advisor in the process.

Business Wire 8 months ago

GLYC
+3.75%
7 Sorry Biotech Stocks Set to Make Investors Sad

Biotech stocks are not for everyone, let’s make that perfectly clear. It’s challenging to invest in a field in which companies – particularly startups – can go for years without seeing a penny of revenue. While there are several outstanding companies from which to choose, the field is also littered with biotech stocks to sell before you get into too much trouble. Biotech stocks represent companies that are in the medical field. They develop and commercialize new medical treatments, drugs, and te

InvestorPlace 8 months ago

TNXP

OVID

GANX
Senior VP & Chief Medical Officer of GlycoMimetics Edwin Rock Buys 81% More Shares

Whilst it may not be a huge deal, we thought it was good to see that the GlycoMimetics, Inc. ( NASDAQ:GLYC ) Senior VP...

Simply Wall St. 9 months ago

GLYC
+3.75%
$GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)$

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

ROCKVILLE, Md., June 04, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced comprehensive results from the company’s pivotal Phase 3 study of uproleselan in R/R AML.

Business Wire 10 months ago

GLYC
+3.75%
$GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024$

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

ROCKVILLE, Md., May 29, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at 8:30am ET to provide a comprehensive overview of data from the company’s pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML).

Business Wire 10 months ago

GLYC
+3.75%
Pipeline Moves: Phase III AML trial fails to meet primary endpoint

The Clinical Trials Arena team evaluates assets in oncology and gastrointestinal disorders.

Clinical Trials Arena 10 months ago

GLDAF

GLYC
+3.75%
Uproleselan’s failed Phase III AML trial shakes up GlycoMimetics’ future

This is the second discontinuation of a late-stage AML trial in 2024, after Gilead stopped magrolimab’s Phase III ENHANCE-3 trial in February.

Clinical Trials Arena 10 months ago

GLYC
+3.75%
GlycoMimetics reports data from Phase III AML treatment trial

The study did not show a statistically significant improvement in overall survival after treatment with the uproleselan regimen.

Clinical Trials Arena 10 months ago

GLYC
+3.75%
$GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)$

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

ROCKVILLE, Md., May 06, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced topline results from its Phase 3 global pivotal study of uproleselan in 388 patients with R/R AML. In the study, uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemothera

Business Wire 10 months ago

GLYC
+3.75%
We're Keeping An Eye On GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 11 months ago

GLYC
+3.75%
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

ROCKVILLE, Md., April 25, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET.

Business Wire 11 months ago

GLYC
+3.75%

Performance Overview

Return	GLYC	S&P 500 (^GSPC)
YTD	-19.24%	-8.81%
1-Year	-91.96%	+3.16%
3-Year	-80.59%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

GlycoMimetics, Inc. (GLYC)

US Penny Stocks To Watch In February 2025

GlycoMimetics and Crescent Biopharma Announce Merger Plans

GlycoMimetics: Q3 Earnings Snapshot

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

US Penny Stocks To Watch In October 2024

GlycoMimetics Announces Merger with Crescent Biopharma

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

7 Sorry Biotech Stocks Set to Make Investors Sad

Senior VP & Chief Medical Officer of GlycoMimetics Edwin Rock Buys 81% More Shares

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

Pipeline Moves: Phase III AML trial fails to meet primary endpoint

Uproleselan’s failed Phase III AML trial shakes up GlycoMimetics’ future

GlycoMimetics reports data from Phase III AML treatment trial

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

We're Keeping An Eye On GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

Performance Overview